PRAX
Price
$258.83
Change
+$2.36 (+0.92%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
7.16B
13 days until earnings call
Intraday BUY SELL Signals
VERA
Price
$29.05
Change
-$2.15 (-6.89%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
2.25B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PRAX vs VERA

PRAX vs VERA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PRAX vs. VERA commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRAX is a Hold and VERA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PRAX with price predictions
Oct 21, 2026

PRAX sees its Stochastic Oscillator climbs out of oversold territory

On October 20, 2026, the Stochastic Oscillator for PRAX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 48 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRAX's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.

Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 258 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for PRAX crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for PRAX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.340) is normal, around the industry mean (2.988). P/E Ratio (-19.789) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VERA with price predictions
Oct 21, 2026

VERA's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for VERA turned positive on October 20, 2026. Looking at past instances where VERA's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VERA's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VERA as a result. In 77 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

Following a +7.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERA advanced for three days, in 242 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

VERA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

VERA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VERA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for VERA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.514) is normal, around the industry mean (2.988). P/E Ratio (-5.315) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VERA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. VERA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
PRAX: Fundamental Ratings
PRAX
OUTLOOK RATING
1..100
62
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
24
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PRAXVERA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (PRAX: $256.47 vs. VERA: $31.20)
Brand notoriety: PRAX and VERA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRAX: 99% vs. VERA: 95%
Market capitalization -- PRAX: $7.16B vs. VERA: $2.25B
PRAX [@Biotechnology] is valued at $7.16B. VERA’s [@Biotechnology] market capitalization is $2.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRAX’s FA Score shows that 2 FA rating(s) are green while VERA’s FA Score has 1 green FA rating(s).

  • PRAX’s FA Score: 2 green, 3 red.
  • VERA’s FA Score: 1 green, 4 red.
According to our system of comparison, PRAX is a better buy in the long-term than VERA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRAX’s TA Score shows that 5 TA indicator(s) are bullish while VERA’s TA Score has 5 bullish TA indicator(s).

  • PRAX’s TA Score: 5 bullish, 3 bearish.
  • VERA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than VERA.

Price Growth

PRAX (@Biotechnology) experienced а +7.30% price change this week, while VERA (@Biotechnology) price change was +16.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.

Reported Earning Dates

PRAX is expected to report earnings on Nov 04, 2026.

VERA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PRAX
Daily Signal:
Gain/Loss:
VERA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with FULC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-3.03%
FULC - PRAX
44%
Loosely correlated
-0.54%
VERA - PRAX
41%
Loosely correlated
+3.79%
BEAM - PRAX
40%
Loosely correlated
-0.36%
PTGX - PRAX
39%
Loosely correlated
+0.07%
CGEM - PRAX
38%
Loosely correlated
+0.40%
More

VERA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VERA has been loosely correlated with KURA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VERA jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VERA
1D Price
Change %
VERA100%
+3.79%
KURA - VERA
45%
Loosely correlated
-1.00%
VKTX - VERA
41%
Loosely correlated
-1.24%
SRRK - VERA
41%
Loosely correlated
+3.97%
TRVI - VERA
41%
Loosely correlated
-0.47%
COGT - VERA
40%
Loosely correlated
+0.61%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ROCQ54.810.46
+0.84%
JPMorgan Nasdaq Equity Premium Yield ETF (ROCQ)
XBOC36.750.13
+0.35%
Innovator U.S. Equity Accelerated 9 Buffer ETF - October (XBOC)
BSMV20.180.05
+0.24%
Invesco BulletShares 2031 Municipal Bond ETF (BSMV)
WMTI20.30-0.01
-0.07%
REX WMT Growth & Income ETF
PFF28.82-0.05
-0.17%
iShares Preferred & Income Securities ETF (PFF)